دورية أكاديمية
أعرض في EDS

Coronavirus-Specific Antibody and T Cell Responses Developed after Sputnik V Vaccination in Patients with Chronic Lymphocytic Leukemia.

التفاصيل البيبلوغرافية
العنوان: Coronavirus-Specific Antibody and T Cell Responses Developed after Sputnik V Vaccination in Patients with Chronic Lymphocytic Leukemia.
المؤلفون: Komissarov AA; I.V. Davydovsky Clinical City Hospital, Moscow Department of Healthcare, 11/6 Yauzskaya Str., 109240 Moscow, Russia.; Laboratory of Atherothrombosis, A.I. Yevdokimov Moscow State University of Medicine and Dentistry, 20 Delegatskaya Str., 127473 Moscow, Russia., Kislova M; Botkin City Hospital, 5/17 2nd Botkinsky Drive, 125284 Moscow, Russia., Molodtsov IA; I.V. Davydovsky Clinical City Hospital, Moscow Department of Healthcare, 11/6 Yauzskaya Str., 109240 Moscow, Russia., Petrenko AA; Botkin City Hospital, 5/17 2nd Botkinsky Drive, 125284 Moscow, Russia.; Russian Medical Academy of Continuous Medical Education, 2/1 Barrikadnaya Str., 123242 Moscow, Russia., Dmitrieva E; Botkin City Hospital, 5/17 2nd Botkinsky Drive, 125284 Moscow, Russia., Okuneva M; Botkin City Hospital, 5/17 2nd Botkinsky Drive, 125284 Moscow, Russia., Peshkova IO; National Research Center for Hematology, 4a Novy Zykovsky Proezd, 125167 Moscow, Russia., Shakirova NT; National Research Center for Hematology, 4a Novy Zykovsky Proezd, 125167 Moscow, Russia., Potashnikova DM; I.V. Davydovsky Clinical City Hospital, Moscow Department of Healthcare, 11/6 Yauzskaya Str., 109240 Moscow, Russia., Tvorogova AV; I.V. Davydovsky Clinical City Hospital, Moscow Department of Healthcare, 11/6 Yauzskaya Str., 109240 Moscow, Russia., Ptushkin VV; Botkin City Hospital, 5/17 2nd Botkinsky Drive, 125284 Moscow, Russia., Efimov GA; National Research Center for Hematology, 4a Novy Zykovsky Proezd, 125167 Moscow, Russia., Nikitin EA; Botkin City Hospital, 5/17 2nd Botkinsky Drive, 125284 Moscow, Russia.; Russian Medical Academy of Continuous Medical Education, 2/1 Barrikadnaya Str., 123242 Moscow, Russia., Vasilieva E; I.V. Davydovsky Clinical City Hospital, Moscow Department of Healthcare, 11/6 Yauzskaya Str., 109240 Moscow, Russia.; Laboratory of Atherothrombosis, A.I. Yevdokimov Moscow State University of Medicine and Dentistry, 20 Delegatskaya Str., 127473 Moscow, Russia.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2022 Dec 27; Vol. 24 (1). Date of Electronic Publication: 2022 Dec 27.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: COVID-19*/prevention & control , Leukemia, Lymphocytic, Chronic, B-Cell* , COVID-19 Vaccines*/immunology, Aged ; Humans ; Antibodies, Viral ; T-Lymphocytes ; Vaccination ; Vaccines, Combined ; Vaccines, Synthetic
مستخلص: The clinical course of the new coronavirus disease 2019 (COVID-19) has shown that patients with chronic lymphocytic leukemia (CLL) are characterized by a high mortality rate, poor response to standard treatment, and low virus-specific antibody response after recovery and/or vaccination. To date, there are no data on the safety and efficacy of the combined vector vaccine Sputnik V in patients with CLL. Here, we analyzed and compared the magnitudes of the antibody and T cell responses after vaccination with the Sputnik V vaccine among healthy donors and individuals with CLL with different statuses of preexposure to coronavirus. We found that vaccination of the COVID-19-recovered individuals resulted in the boosting of pre-existing immune responses in both healthy donors and CLL patients. However, the COVID-19-naïve CLL patients demonstrated a considerably lower antibody response than the healthy donors, although they developed a robust T cell response. Regardless of the previous infection, the individuals over 70 years old demonstrated a decreased response to vaccination, as did those receiving anti-CD20 therapy. In summary, we showed that Sputnik V, like other vaccines, did not induce a robust antibody response in individuals with CLL; however, it provided for the development of a significant anti-COVID-19 T cell response.
References: Blood. 2013 Feb 28;121(9):1612-21. (PMID: 23247726)
Clin Infect Dis. 2021 Feb 1;72(3):463-471. (PMID: 32463435)
Blood Cancer J. 2021 Jul 30;11(7):136. (PMID: 34330895)
Eur J Haematol. 2018 Apr;100(4):325-334. (PMID: 29285806)
Blood. 2022 Feb 3;139(5):678-685. (PMID: 34861036)
Open Forum Infect Dis. 2021 Jun 30;8(7):ofab353. (PMID: 34337100)
Eur J Haematol. 2022 Feb;108(2):91-98. (PMID: 34717004)
Leukemia. 2021 Sep;35(9):2703-2705. (PMID: 33986431)
Am J Hematol. 2021 Oct 1;96(10):1195-1203. (PMID: 34185336)
Blood Adv. 2022 Mar 22;6(6):1671-1683. (PMID: 35073571)
Br J Haematol. 2022 Apr;197(1):41-51. (PMID: 34962656)
PLoS One. 2014 Dec 15;9(12):e114966. (PMID: 25506837)
J Hematol Oncol. 2022 Jan 9;15(1):3. (PMID: 35000597)
J Clin Med. 2022 May 16;11(10):. (PMID: 35628927)
Clin Microbiol Infect. 2022 Mar;28(3):398-404. (PMID: 34838783)
Lancet. 2021 Feb 20;397(10275):671-681. (PMID: 33545094)
Leuk Lymphoma. 2022 Jul;63(7):1607-1616. (PMID: 35156528)
Lancet. 2020 Sep 26;396(10255):887-897. (PMID: 32896291)
Lancet. 2021 Apr 10;397(10282):1347-1348. (PMID: 33770519)
Blood. 2022 Jul 21;140(3):236-252. (PMID: 35544585)
Lancet Reg Health Am. 2022 Feb;6:100123. (PMID: 34841388)
Clin Infect Dis. 2022 Aug 24;75(1):e1-e9. (PMID: 35435222)
Br J Haematol. 2022 Feb;196(3):577-584. (PMID: 34872162)
Blood Adv. 2022 Apr 12;6(7):2014-2034. (PMID: 34852173)
Cancer Cell. 2021 Aug 9;39(8):1031-1033. (PMID: 34331856)
Blood Adv. 2022 Jan 11;6(1):207-211. (PMID: 34844264)
Blood. 2021 Jun 10;137(23):3165-3173. (PMID: 33861303)
Blood. 2020 Dec 17;136(25):2881-2892. (PMID: 33113551)
Haematologica. 2022 Mar 01;107(3):625-634. (PMID: 34320789)
Leukemia. 2021 Mar;35(3):737-746. (PMID: 32555297)
J Clin Invest. 2008 Jul;118(7):2427-37. (PMID: 18551193)
Blood Adv. 2022 Feb 22;6(4):1207-1211. (PMID: 34872103)
معلومات مُعتمدة: DC № DZM-30-3 from 13.08.2020 Moscow Department of Healthcare; agreement № 2312-29/22 Moscow Center for Healthcare Innovations
فهرسة مساهمة: Keywords: COVID-19; ELISpot; SARS-CoV-2; T cells; antibody; chronic lymphocytic leukemia; immune response; vaccine
المشرفين على المادة: 0 (Antibodies, Viral)
0 (Vaccines, Combined)
0 (Gam-COVID-Vac vaccine)
0 (COVID-19 Vaccines)
0 (Vaccines, Synthetic)
تواريخ الأحداث: Date Created: 20230108 Date Completed: 20230111 Latest Revision: 20230111
رمز التحديث: 20230112
مُعرف محوري في PubMed: PMC9820366
DOI: 10.3390/ijms24010416
PMID: 36613860
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms24010416